CPCozumel S. Pruette

Cozumel S. Pruette

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cozumel S. Pruette has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Collaborative decision-making among pediatric nephrology providers: a qualitative study

    by Cyd K. Eaton, Cozumel S. Pruette, Hyeyoung Ryu, Chelsea Ng, Zixuan Xu, Qiulin Qu, Jaime Snyder, Wanda Pratt, Aaron Wightman, Ari H. Pollack

  • Subcutaneous Alemtuzumab as Salvage Therapy for Acute Kidney Transplant Rejection Following Thymoglobulin Anaphylaxis: A Pediatric Case Report

    by Kevin W. O'COnnor, Serena Bagnasco, Cozumel Pruette, Elizabeth Goswami, Olga Charnaya

    Background: Acute kidney allograft rejection is a significant cause of graft dysfunction in pediatric transplant recipients. Standard of care for moderate to severe acute T‐cell‐mediated rejection among pediatric transplant recipients includes lymphocyte‐depleting agents such as rabbit anti‐thymocyte globulin (rATG). However, intolerance to or contraindications to rATG may limit its use and necessitate alternative immunosuppressive strategies. Alemtuzumab, a humanized monoclonal antibody targeting CD52, induces profound depletion of T‐ and B‐ lymphocytes and has been used in the transplantation setting. However, data remain limited for pediatric rejection, and the precise role for alemtuzumab is not well defined. Case Presentation: We report a 12‐year‐old male with end‐stage kidney disease secondary to congenital renal dysplasia who underwent deceased donor kidney transplantation and presented 9 years post‐transplant with acute allograft dysfunction. Evaluation revealed a rise in serum creatinine, subtherapeutic tacrolimus levels, and increased donor‐specific antibodies. Kidney biopsy demonstrated Banff grade IIA T‐cell‐mediated rejection with features of antibody‐mediated rejection. Initial treatment included high‐dose corticosteroids and intravenous immunoglobulin. rATG therapy was initiated but discontinued due to anaphylaxis. The patient subsequently received a 30‐mg dose of subcutaneous alemtuzumab, which was well tolerated. B‐ and T‐lymphocyte populations were suppressed on flow cytometry analysis. Kidney function significantly improved, repeat biopsy showed marked improvement in tubulointerstitial inflammation, and graft function remained stable at follow‐up. Conclusions: This case highlights the potential role of alemtuzumab as an alternative lymphocyte‐depleting therapy for the treatment of acute rejection in pediatric kidney transplant recipients, particularly when rATG is contraindicated. Moreover, treatment with alemtuzumab may preclude the need for additional B‐cell directed therapy in cases of mixed T‐cell‐ and antibody‐mediated rejection. Further studies are needed to better define its safety, efficacy, and optimal role in this population.


  • Open Access

    Co-designing for the Triad: Design Considerations for Collaborative Decision-Making Technologies in Pediatric Chronic Care

    by Ray-Yuan Chung, Jaime Snyder, Zixuan Xu, Daeun Yoo, Athena C. Ortega, Wanda Pratt, Aaron Wightman, Ryan Hutson, Cozumel Pruette, Ari Pollack


  • Local environment, socioeconomic status, and health literacy: key modifiers of adherence in pediatric nephrology

    by Cyd K. Eaton, Cozumel S. Pruette

    Pediatric nephrology patients have high rates of treatment nonadherence, thus increasing their risk for poor health outcomes. Key modifiers of adherence among pediatric nephrology patients include local environment (place of residence, school setting, clinic setting), socioeconomic status, and health literacy. Where patients live affects access to health care, community, and school resources that support adherence and disease management. Socioeconomic challenges, such as lower income, food insecurity, and housing instability, may lead patients and families to prioritize immediate survival needs over adherence. Lower health literacy is common among pediatric nephrology patients and their caregivers and may contribute to difficulties communicating with care teams, understanding health information, and implementing medical recommendations. This educational review aims to (1) conceptualize local environment, socioeconomic status, and health literacy, as well as their interconnections, within an established socio-ecological framework of the individual, family, community, and health care system factors impacting pediatric adherence, (2) synthesize recent literature on the influence of these domains on adherence in pediatric nephrology, and (3) highlight strategies to mitigate barriers within each domain and promote adherence among pediatric nephrology patients and their families. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information

  • Open Access

    Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome

    by Tiffany Tu, Alejandro Ochoa, Amika Sood, Ashley Drabik, Megan Chryst-Stangl, Brandon Lane, Guanghong Wu, Frank Donovan, Ursula Harper, Settara Chandrasekharappa, et al.

    Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract


  • Open Access

    Tacrolimus IPV Group Membership Does Not Consistently Track With Electronically Monitored or Self-reported Adherence in Adolescent and Young Adult Kidney Transplant Recipients

    by Cyd K. Eaton, Cozumel S. Md Pruette, Kristin A. Riekert, Nazanin Yousefzadeh, Ahna L. Pai, Sandra Md Amaral, Vikas R. Dharnidharka, Bärbel Knäuper, Jodi M. Smith, Susan L. Furth, et al.

    Background.: High intrapatient variability (IPV) of tacrolimus trough concentrations (SD ≥ 2, coefficient of variation (CV%) ≥ 30) is associated with rejection and graft loss and may indicate nonadherence. However, the association between tacrolimus IPV and electronically monitored or self-reported adherence is unknown. Methods.: This secondary analysis of the TAKE-IT (Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial) compared electronically monitored and self-reported adherence between participants with high and low tacrolimus IPV among 103 adolescent and young adult kidney transplant recipients (mean age = 15.18 y, 59% male, 60% White, 65% >1-y posttransplant). Results.: Electronically monitored daily taking and timing adherence were not significantly associated with tacrolimus IPV group in binomial generalized linear mixed effects models: Participants with tacrolimus SD ≥ 2 or CV% ≥ 30 were no less likely to take each daily dose than those below these cutoffs (SD < versus ≥ 2: odds ratio [OR]; 0.84, 95% confidence interval [CI], 0.48-1.47; P = 0.54 and CV% < versus ≥ 30: OR, 0.72; 95% CI, 0.43-1.21; P = 0.22). Participants with tacrolimus SD ≥ 2 or CV% ≥ 30 were no less likely to take each daily dose on time than those below these cutoffs (SD < versus ≥ 2: OR, 0.70; 95% CI, 0.40-1.23; P = 0.21 and CV% < versus ≥ 30: OR, 0.68; 95% CI, 0.40-1.16; P = 0.15). Electronically monitored averages of doses taken, doses taken early/late, and differences from expected dose time were associated with tacrolimus IPV (P < 0.05) but were poor classifiers of IPV group membership (area under the curve < 0.70). Self-reported adherence was not associated with tacrolimus IPV. Conclusions.: Tacrolimus IPV group membership does not consistently track with behavioral adherence measures. Relying on tacrolimus IPV group membership may misidentify nonadherence in adolescent and young adult kidney transplant recipients.


  • Extended‐release tacrolimus dosing and outcomes in pediatric and young adult transplant recipients – A single‐center experience

    by Xinyi Huang, Katherine Hapgood, Kari Allan, Cozumel Pruette, Elizabeth Goswami

    Background: Published data on LCP‐tacrolimus (LCPT) in the pediatric population are limited.Methods: This single‐center, retrospective, observational study describes LCPT doses needed to reach therapeutic ranges in pediatric and young adult kidney and liver transplant recipients in both de novo usage and conversion from immediate‐release tacrolimus (IR‐Tac). Adverse outcomes up to 12 months after LCPT initiation were also evaluated.Results: Forty‐one transplant recipients (30 kidney, 11 liver) were included. The median initial doses of LCPT were 0.034 mg/kg (IQR 0.019) de novo and 0.09 mg/kg (IQR = 0.076) converted. The median doses at first therapeutic level were 0.086 mg/kg (IQR 0.028) de novo and 0.1 mg/kg (IQR 0.066) converted. The median LCPT:IR‐Tac conversion ratio initially was 0.7 and 0.75 at therapeutic levels. The rate of AKI per 100 days of exposure to IR‐Tac was 0.546 and 0.439 on LCPT. The percentage of patients with rejection was not different before and after conversion (clinical rejection 8.6% [n = 3] vs 11.4% [n = 4], p = .6; biopsy‐proven rejection 2.9% [n = 1] vs 11.4% [n = 4], p = .11). One patient had graft loss unrelated to rejection, and the graft was explanted.Conclusion: In this study, pediatric and young adult abdominal transplant recipients had therapeutic tacrolimus levels at LCPT doses below the adult‐labeled dose; the conversion ratio from IR‐Tac to LCPT at therapeutic level was similar. There were no identified safety concerns in de novo or converted LCPT use in pediatric and young adult patients.


  • Empowering patients to adhere to their treatment regimens: A multifaceted approach

    by Cozumel S. Pruette, Sandra Amaral

    It is well‐recognized that adolescence and early adulthood are a high‐risk period for non‐adherence with treatment regimens in solid organ transplant recipients, leading to high rates of rejection and graft loss (Transplantation, 92, 2011, 1237; Pediatr Transplant, 9, 2005, 381; Transplantation, 77, 2004, 769). Preventing medication non‐adherence is the holy grail of transplant adolescent care. If we can determine how best to support our patients in taking their daily medications as prescribed, we can improve long‐term health, reduce need for re‐transplantation, and reduce healthcare costs. In the last few years, several studies have provided us with additional insights into potentially effective interventions and have highlighted existing gaps in knowledge. This article reviews recent literature published over the last 5 years on the topic of adherence in transplant recipients, highlighting insights and opportunities to promote adherence at the individual patient level, family level, healthcare system level, and community level. Above all, the recent work that is highlighted suggests that adherence interventions for prevention and treatment must be multifaceted, individualized, and longitudinal to be effective.


  • Engagement and Affective Communication During Pediatric Nephrology Clinic Visits: Associations with Medication Adherence

    by Trevor W. Glenn, Kristin A. Riekert, Debra Roter, Michelle N. Eakin, Cozumel S. Pruette, Tammy M. Brady, Susan R. Mendley, Shamir Tuchman, Barbara A. Fivush, Cyd K. Eaton